特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

腹膜炎:パイプライン製品の分析

Peritonitis - Pipeline Review, H1 2020

発行 Global Markets Direct 商品コード 360906
出版日 ページ情報 英文 45 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.57円で換算しております。
腹膜炎:パイプライン製品の分析 Peritonitis - Pipeline Review, H1 2020
出版日: 2020年05月30日 ページ情報: 英文 45 Pages
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
概要

腹膜炎は、腹膜の炎症で、2種類の腹膜炎があります。 自然細菌性腹膜炎(SBP)は、腹腔液の感染症によるものです。二次腹膜炎は、通常、消化管から広がった感染症によるものです。症候は、腹部膨満、吐き気および嘔吐、下痢、疲労、熱と寒けなどがあります。治療には抗生物質を用います。

当レポートでは、腹膜炎の治療薬の開発状況について調査分析しており、パイプライン製品の概要、治療薬の開発に携わっている主な企業および薬剤のプロファイル、最新のパイプライン動向などの情報を提供しています。

イントロダクション

  • 調査範囲

腹膜炎の概要

治療薬の開発

  • パイプライン製品の概要
  • 企業別のパイプライン
  • 大学/研究機関で開発されたパイプライン
  • 企業で開発中の製品
  • 大学/研究機関で開発中の製品

治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

腹膜炎の治療薬開発に従事している企業

  • Adenium Biotech ApS
  • Allergan Plc
  • GlaxoSmithKline Plc
  • Oncodesign SA
  • SynAct Pharma AB

薬剤プロファイル

腹膜炎:休止中のプロジェクト

腹膜炎:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

List of Tables

  • Number of Products under Development for Peritonitis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Peritonitis - Pipeline by Arrevus Inc, H1 2020
  • Peritonitis - Pipeline by Ayuvis Research Inc, H1 2020
  • Peritonitis - Pipeline by GlaxoSmithKline Plc, H1 2020
  • Peritonitis - Pipeline by Hunan Sanqing Pharmaceutical Co Ltd, H1 2020
  • Peritonitis - Pipeline by Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd, H1 2020
  • Peritonitis - Pipeline by Nosopharm SAS, H1 2020
  • Peritonitis - Pipeline by Oncodesign SA, H1 2020
  • Peritonitis - Pipeline by Reponex Pharmaceuticals Aps, H1 2020
  • Peritonitis - Pipeline by SynAct Pharma AB, H1 2020
  • Peritonitis - Dormant Projects, H1 2020

List of Figures

  • Number of Products under Development for Peritonitis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
目次
Product Code: GMDHC12198IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peritonitis - Pipeline Review, H1 2020, provides an overview of the Peritonitis (Gastrointestinal) pipeline landscape.

Peritonitis is inflammation of the peritoneum. There are two types of peritonitis. Spontaneous bacterial peritonitis (SBP) is the result of an infection of the fluid in peritoneal cavity. Secondary peritonitis is usually due to an infection that has spread from digestive tract. Symptoms include abdominal bloating, nausea and vomiting, diarrhea, fatigue, fever and chills. Treatment includes antibiotics.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peritonitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Peritonitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peritonitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Peritonitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 1 and 8 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Peritonitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Peritonitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Peritonitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Peritonitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Peritonitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Peritonitis (Gastrointestinal)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Peritonitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Peritonitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Peritonitis - Overview
    • Peritonitis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Peritonitis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Peritonitis - Companies Involved in Therapeutics Development
    • Arrevus Inc
    • Ayuvis Research Inc
    • GlaxoSmithKline Plc
    • Hunan Sanqing Pharmaceutical Co Ltd
    • Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd
    • Nosopharm SAS
    • Oncodesign SA
    • Reponex Pharmaceuticals Aps
    • SynAct Pharma AB
  • Peritonitis - Drug Profiles
    • AP-1189 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARV-1502 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aspoxicillin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVR-25 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ceforanide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • molgramostim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NOSO-502 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ODS-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit NLRP3 for Inflammatory Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SRT-3025 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Peritonitis - Dormant Projects
  • Peritonitis - Product Development Milestones
    • Featured News & Press Releases
      • Jun 19, 2016: Reponex Pharmaceuticals: The Danish Medicines Agency has approved the clinical trial protocol for the peritonitis project
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer